16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Extraction and purification of 1-hydroxymidazolam glucuronide from ultrafiltrate

      abstract
      1 , , 2 , 3 , 1
      Critical Care
      BioMed Central
      30th International Symposium on Intensive Care and Emergency Medicine
      9–12 March 2010

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction We developed a technique for detection of MDZ and 1-hydroxymidazolam glucuronide (1-OHMG). No commercial source of 1-OHMG prevented assay development. 1-OHMG had pharmacological activity and is renally excreted. We postulated that ultrafiltrate (UFR) would be rich in 1-OHMG. We describe a method to purify 1-OHMG from UFR. Methods Ethics approval was granted. To purify, UFR was extracted on a C-18 column, it was washed and eluted. HPLC-MS separation was performed. The 1-OHMG (mol. wt 517/518 in MS) was desiccated and re-dissolved four times to maximise purity. Electrospray (ESI) mass spectrometry (MS) characterised 1-OHMG. The purity was calculated using NMR. A calibration plot of 1-OHMG, MDZ and DZP (internal standard) for HPLC-MS was performed. Results 1-OHMG identity was confirmed using MS/MS (Figure 1). Two milligrams of 1-OHMG was purified from 5,000 ml UFR. The 1-OHMG was 98% pure (NMR). The extinction coefficient was identical to MDZ. The calibration plot resulted in correlation of 0.912. The assay was applied into clinical practice, to report sera and UFR levels. Figure 1 Centroided MS of purified 1-OHMG. Conclusions We were able to extract and purify an active drug metabolite from UFR. Five litres of UFR resulted in 2 mg 1-OHMG. This is a potentially rich source of drugs or drug metabolites, allowing pharmacokinetic studies greatly required in critical illness.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Differentiating midazolam over-sedation from neurological damage in the intensive care unit

          Introduction Midazolam is used routinely to sedate patients in the intensive care unit (ICU). We suspected that midazolam over-sedation was occurring in the ICU of the Guy's and St. Thomas' Trust and that it could be difficult to differentiate this from underlying neurological damage. A sensitive assay for detecting midazolam and 1-hydroxymidazolam glucuronide (1-OHMG) in serum was developed and applied in the clinical setting. Methods In the present study we evaluated a series of cases managed in a mixed medical, surgical and trauma ICU. Serum was collected from 26 patients who received midazolam, were 'slow to wake' and in whom there was suspicion of neurological damage. Patient outcome was followed in terms of mortality, neurological recovery and neurological damage on discharge. Results Out of 26 patients, 13 had detectable serum levels of midazolam and/or 1-OHMG after a median of 67 hours (range 36–146 hours) from midazolam cessation. Of these 13 patients in whom midazolam/1-OHMG was detectable, 10 made a full neurological recovery. Of the remaining 13 patients with no detectable midazolam/1-OHMG, three made a full neurological recovery; 10 patients were subsequently found to have suffered neurological damage (P < 0.002), eight of whom died and two were discharged from the ICU with profound neurological damage. Conclusion These findings confirm that prolonged sedation after midazolam therapy should be considered in the differential diagnosis of neurological damage in the ICU. This can be reliably detected by the assay method described. The effects of midazolam/1-OHMG persist days after administration of midazolam has ceased. After prolonged sedation has been excluded in this patient group, it is highly likely that neurological damage has occurred.
            Bookmark

            Author and article information

            Conference
            Crit Care
            Critical Care
            BioMed Central
            1364-8535
            1466-609X
            2010
            1 March 2010
            : 14
            : Suppl 1
            : P512
            Affiliations
            [1 ]Guy's and St Thomas' NHS Foundation Trust, London, UK
            [2 ]Kingston University, London, UK
            [3 ]King's College, London, UK
            Article
            cc8744
            10.1186/cc8744
            2934138
            7d255169-7e9c-45f1-b31d-c494f4890639
            Copyright ©2010 BioMed Central Ltd.
            30th International Symposium on Intensive Care and Emergency Medicine
            Brussels, Belgium
            9–12 March 2010
            History
            Categories
            Poster Presentation

            Emergency medicine & Trauma
            Emergency medicine & Trauma

            Comments

            Comment on this article